MCM
GCVRZ

Mainstay Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Mainstay Capital Management’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-415
Closed -$14K – 436
2018
Q3 		$14K Buy
415
+315
+315% +$169 0.01% 320
2018
Q2 		$0 Hold
100
– – ﹤0.01% 459
2018
Q1 		$0 Hold
100
– – ﹤0.01% 451
2017
Q4 		$0 Buy
+100
New +$38 ﹤0.01% 413

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Mainstay Capital Management's GCVRZ Position: Q4 2018 in Review

Mainstay Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2018, closing a stake of 415 shares — an estimated $14K sold.

Mainstay Capital Management first reported a position in GCVRZ in Q4 2017 and held it in 4 quarters. The position peaked at $14K in Q3 2018. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2018.

  • Mainstay Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 415 Sanofi Contingent Value Rights shares in Q4 2018, an estimated $14K.
  • Mainstay Capital Management first reported a position in Sanofi Contingent Value Rights in Q4 2017 and held it in 4 quarters.
  • Mainstay Capital Management's Sanofi Contingent Value Rights position peaked at $14K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.